Nutex Health ($NUTX) Arbitration Vendor Fraud and Misrepresentation of Growth Case

The court has appointed the lead plaintiff to represent the class.

S.D. Texas

Court

4:25-cv-03999

Case number

08/08/2024

Class period Start

08/14/2025

Class period End

10/21/2025

Lead Plaintiff motion deadline

$NUTX investors filed a claim against Nutex Health for inflating revenues through improper arbitration practices, concealing weak internal controls, and misstating financial results.
After a short-seller report exposed Nutex’s reliance on a vendor accused of fraudulent billing and the company delayed filing its quarterly report, $NUTX collapsed more than 26% across July–August 2025.
$NUTX investors can join this case to be notified about potential recovery.
Case Details:

Between August 8, 2024, and August 14, 2025, Nutex Health promoted strong growth by highlighting its “arbitration strategy” under the No Surprises Act, claiming it achieved an 80% success rate and hundreds of millions in additional revenue. Executives told investors these arbitration recoveries represented sustainable value and assured the market that material weaknesses in internal controls were being remediated.

In reality, Nutex’s arbitration results were tied to HaloMD, a billing vendor accused in multiple lawsuits of flooding the arbitration system with false claims and fabricating eligibility. Blue Orca Capital’s July 22, 2025 report revealed Nutex’s undisclosed reliance on HaloMD and warned the company could face litigation and clawbacks. Nutex shares fell 10.05% that day.

On August 14, 2025, Nutex further rattled investors by delaying its Q2 2025 Form 10-Q due to improper accounting for stock-based compensation. When the company failed to rebut Blue Orca’s allegations, shares plunged another 16.39%.

Based on these events, $NUTX investors filed a claim against Nutex Health, alleging the company:
It misrepresented the sustainability of its arbitration-driven revenues.
It concealed material weaknesses in internal controls and misstated compensation accounting.
It artificially inflated its stock price through reliance on a vendor accused of systemic fraud.
Investors argue Nutex misled the market about its financial health and revenue quality, leaving shareholders with steep losses when the truth emerged.

Case Type

US Securities Class Action

Case Status

Lead Plaintiff Appointed

Alleged Offence

Misleading Statements,

Financial Misrepresentation

Suspected Party

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

08/15/2025

Filing date

08/22/2025

Lead Plaintiff Deadline

10/21/2025

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.